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Stromal senescence establishes an
immunosuppressive microenvironment that
drives tumorigenesis
Megan K. Ruhland1, Andrew J. Loza2, Aude-Helene Capietto3, Xianmin Luo1, Brett L. Knolhoff2,
Kevin C. Flanagan1, Brian A. Belt4, Elise Alspach5, Kathleen Leahy1, Jingqin Luo6,7, Andras Schaffer5,
John R. Edwards2,8, Gregory Longmore2,7,9, Roberta Faccio3,7, David G. DeNardo2,5,7,9 & Sheila A. Stewart1,2,7,9

Age is a signiﬁcant risk factor for the development of cancer. However, the mechanisms that
drive age-related increases in cancer remain poorly understood. To determine if senescent
stromal cells inﬂuence tumorigenesis, we develop a mouse model that mimics the aged skin
microenvironment. Using this model, here we ﬁnd that senescent stromal cells are sufﬁcient
to drive localized increases in suppressive myeloid cells that contributed to tumour
promotion. Further, we ﬁnd that the stromal-derived senescence-associated secretory
phenotype factor interleukin-6 orchestrates both increases in suppressive myeloid cells and
their ability to inhibit anti-tumour T-cell responses. Signiﬁcantly, in aged, cancer-free
individuals, we ﬁnd similar increases in immune cells that also localize near senescent stromal
cells. This work provides evidence that the accumulation of senescent stromal cells is
sufﬁcient to establish a tumour-permissive, chronic inﬂammatory microenvironment that
can shelter incipient tumour cells, thus allowing them to proliferate and progress unabated
by the immune system.
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A

ge signiﬁcantly affects an individual’s risk for developing
cancer1. The factors that contribute to age-related
increases in cancer are thought to include accumulation
of stochastic mutations within incipient tumour cells and
collaborative stromal changes that together drive tumorigenesis.
While a plethora of cell-autonomous mutations have been shown
to contribute to cellular transformation, how an aging stromal
compartment develops and supports tumour outgrowth remains
poorly understood. Inﬂammation may provide a link that
explains how changes in the stromal compartment contribute
to age-related increases in tumour development. Indeed, older
individuals experience systemic changes in mediators of chronic
inﬂammation including increases in cytokines and various
immune cells such as immunosuppressive myeloid cells2–6. It
remains unclear what drives these increases, but one contributing
factor may be the accumulation of senescent cells that is known to
occur with age7–9. Supporting the putative role of senescent cells
in age-related increases in tumorigenesis is recent work showing
that depletion of senescent cells in mice leads to a signiﬁcant
reduction in tumorigenesis10. However, the mechanisms that
underlie this reduction remain to be addressed.
Senescent cells are metabolically active cells that are characterized by an irreversible growth arrest. In addition, senescent
cells express the cell cycle inhibitor p16INK4A (p16), senescenceassociated b-galatosidase (SA-bgal), and an altered expression
proﬁle known as the senescence-associated secretory phenotype
(SASP)11. Among the SASP cytokines, interleukin-6 (IL-6) is
considered a canonical inﬂammatory factor12. IL-6 is elevated
with age and coincides with increases in both circulating
immunosuppressive myeloid cells and cancer incidence2,6. The
possibility that stromal-derived SASP factors, including IL-6,
mediate the establishment of chronic inﬂammation that
predisposes a tissue to tumour outgrowth is intriguing.
Senescence plays a paradoxical role in tumorigenesis, being both
tumour-promoting and tumour-suppressive depending on the cell
in which senescence occurs. Indeed, in some tumour models,
senescent neoplastic cells can stimulate immune-mediated tumour
cell clearance and thus, in this context, senescence functions as a
potent tumour-suppressive mechanism13. However, in immunecompromised settings, when admixed with tumour cells, senescent
stromal cells actively promote tumour growth through paracrine
mechanisms14–19. These ﬁndings raise two important questions in
the setting of an active immune system; (1) how do incipient
tumour cells that arise within a senescent stromal compartment
evade immune clearance and (2) can senescence within the stromal
compartment affect the host immune response and adopt a
pro-tumorigenic role? To address these important questions, we
created an immune-competent mouse model to interrogate the
role senescent stromal cells play in the preneoplastic, inﬂammatory
microenvironment. Upon inducing senescence in the
mesenchymal compartment, we ﬁnd that in the absence of
existing tumour cells, senescent stromal cells are sufﬁcient to create
an immunosuppressed environment, reminiscent of what we ﬁnd
in aging human skin. Further, we ﬁnd that senescence-established
immunosuppression facilitated tumour outgrowth by increasing
myeloid-derived suppressor cells (MDSCs) capable of inhibiting
CD8 þ T-cell function. Together, these ﬁndings suggest a
mechanism whereby senescent stromal cells contribute to
age-related increases in tumorigenesis through the creation of
local regions of immunosuppression.
Results
Senescent stromal cells drive increased inﬂammation. To
determine if stromal-derived SASP affects the immune
microenvironment, we developed a genetically engineered mouse
2

to spatially and temporally control senescence activation
exclusively in the stromal compartment20. Mice bearing a
stromal-speciﬁc, tamoxifen (TAM)-inducible Cre-recombinase
under the control of the pro-alpha 2(I)collagen promoter21 were
mated to mice that conditionally activate expression of the
cell cycle inhibitor p27Kip1 from the ROSA26 locus (ROSAloxstop-lox-p27Kip1IRESGFP) (refs 21,22). The p27Kip1 allele was
used because it robustly activates senescence and SASP expression
reminiscent of cells induced to senescence through telomere
dysfunction, DNA damage-induced senescence and oncogeneinduced senescence23. To ﬁrst verify the relevance of p27Kip1 in
age-related senescence, we stained human skin samples and
found age-dependent increases in stromal p27Kip1 expression
(Supplementary Fig. 1a,b). Thus p27Kip1 is a valid model for
interrogating senescence-associated phenotypes.
To establish the affect of stromal senescence on tumorigenesis,
we ﬁrst characterized our mouse model, termed the FASST
mouse (ﬁbroblasts accelerate stromal supported tumorigenesis),
which upon TAM administration activates the p27Kip1 allele
within cells of mesenchymal origin. Tissue samples were
obtained from 6-week-old FASST and littermate control mice 2
weeks after transgene activation with TAM. To identify senescent
cells, skin sections were stained for the senescence marker,
senescence-associated b-galactosidase (SA-bgal) (Fig. 1a)7. We
observed a signiﬁcant increase in the number of senescent
cells within the skin stroma of FASST mice compared with
littermate controls (Fig. 1a,b) as well as within the mammary
gland, lung (data not shown) and bone20, reﬂecting the
mesenchymal nature of the collagen promoter used in our
system. Importantly, this ﬁnding mimicked the mosaic pattern of
senescent cell accumulation observed in aged human tissues7.
Senescent stromal cells display an altered, pro-tumorigenic gene
expression proﬁle that is characterized by the increased expression
of numerous mitogens, extracellular matrix remodelling enzymes,
cytokines and chemokines14–19. To determine if senescent stromal
cells from FASST mice displayed a similar phenotype, we next
performed RNA sequencing (RNA-Seq) analysis on TAM treated
mouse skin ﬁbroblasts (MSFs) (Fig. 1c). Our analysis demonstrated
that mitogens (including PDGFa and IGF2), extracellular matrix
remodelling enzymes (including MMP3), and numerous cytokines
and chemokines were increased in senescent versus non-senescent
MSFs (data not shown). Gene set enrichment analysis (GSEA)
revealed a speciﬁc enrichment of factors in the JAK-STAT pathway
known to modulate immune cells (Po10  3, GSEA)24,25.
Leading-edge analysis suggested multiple genes contributed to
the core enrichment of the pathway (Supplementary Fig. 2a).
Compared with non-senescent MSFs, senescent MSFs more
robustly expressed the canonical SASP factor IL-6 as well as
other inﬂammatory mediators including CXCL5, CXCL1,
CCL2 and CCL5 (Fig. 1c). Upregulation of factors was validated
using quantitative reverse transcription PCR (qRT-PCR)
(Supplementary Fig. 2b).
Given the increased expression of inﬂammatory cytokines
detected in senescent versus non-senescent MSFs, we next asked
if these cells played a role in regulating local inﬂammation. Using
an antibody against CD45, a pan-leukocyte marker, we found 3.5
times as many immune cells in the skin of FASST mice than in
littermate controls (Fig. 1d,e), suggesting senescent stromal cells
promote local inﬂammation. In addition, the increased CD45 þ
cells appeared to preferentially localize around senescent
ﬁbroblasts. To directly measure this association, we used a spatial
analysis technique to examine the relative localization of GFP þ
senescent cells (green) and CD45 þ immune cells (red) in
co-stained FASST skin (Fig. 1f). An association score for each
sample was computed by taking the difference between the
observed and random chance nearest-neighbour distances
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Figure 1 | Senescent stromal cells induce local inﬂammation. (a) Senescence activation in FASST or littermate mice. Senescence-associated
b-galactosidase (SA-bgal) staining (blue) of skin (arrows). Scale bar, 100 or 10 mm in zoomed images. * site of zoomed image. Representative images.
(b) Quantiﬁcation of SA-bgal þ cells per  20 ﬁeld of view (FOV). *P-valueo0.05 by Student’s t-test. Error bars represent s.e.m. Representative
experiment. n ¼ 10. (c) RNA-seq shows expression of multiple cytokines and chemokines signiﬁcantly increased in senescent MSFs (FDRo0.05, edgeR).
Graph is log fold change (logFC) expression in Sen compared with Non-Sen MSFs. n ¼ 3. (d) CD45 IHC staining of skin from FASST or littermate mice.
Arrows indicate CD45 þ cells. Scale bar, 100 mm. Representative images. (e) Quantiﬁcation of CD45 þ cells per  20 FOV. *P valueo0.05 by Student’s
t-test. Error bars represent s.e.m. Representative experiment. n ¼ 9. (f) Schematic of transgenic expression cassette (top). Below, IF co-staining for
transgenic GFP expression (green) and CD45 þ cells (red). Nuclei stained with DAPI (blue). Scale bar, 100 or 10 mm in zoomed image. * site of zoomed
images (right). Representative image. (g) Spatial analysis of CD45 þ leukocytes and GFP þ stromal cells. Data show median distance between
CD45 þ leukocytes and GFP þ stromal cells (green) is signiﬁcantly smaller than chance (mean normalized association score 3.5, 95% conﬁdence interval
(CI) 2.4–4.6). In the absence of senescent cells (littermate control), the observed distance distribution of immune cells to the epithelial layer (orange) is
not signiﬁcantly different from random (Epithelium-CD45) (mean normalized association score ¼ 1.0, 95% CI  0.2 to 2.2). Immune cell-immune
cell (CD45-CD45) distances (red) are not signiﬁcantly different from random (mean association statistic ¼ 0.2, 95% CI  0.5 to 0.9). Error bars represent
s.d. n ¼ 6–9. (h) Flow cytometry analysis of FASST and littermate control skin. Data represents CD45 þ , CD45 þ CD11b þ or CD45 þ CD3 þ populations as a
percentage of live cells per mouse skin. *P value o0.05 by Student’s t-test. Data are presented as mean % þ s.e.m. shown as error bars. n ¼ 3.
FDR, false discovery rate.
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normalized by the s.d. that was determined by random sampling.
Positive values indicate association of the two cell types, values of
zero indicate the distance distribution matches what is expected
by chance, and negative values indicate repulsion. The observed
median distance from each immune cell to the nearest senescent
ﬁbroblast was found to be signiﬁcantly smaller than chance would
predict in all samples (values40) (Fig. 1g). Spatial analysis of
littermate control skin showed that other potential inﬂuences on
localization including a bias towards the epithelial layer (orange)
or immune cell to immune cell preferential interactions (red)
were not present (Fig. 1g). This increase in immune cell
number, and localization bias towards senescent cells within
FASST skin, strongly suggested that senescent stromal-derived
SASP orchestrates a localized inﬂammatory environment.
Increases in inﬂammation and a notable shift in immune cell
localization led us to next perform polychromatic ﬂow cytometry
staining to identify the cell types present in the senescent
microenvironment. We stained cells derived from the skin of
FASST and littermate mice with immune cell markers and
performed ﬂow analysis. Similar to our immunohistochemistry
(IHC) analyses, ﬂow cytometric proﬁling revealed a signiﬁcant
increase in CD45 þ cells in the FASST skin compared with
littermate controls (Fig. 1h). Further analysis revealed that many
of these cells were CD11b þ myeloid cells. We also found that
CD45 þ CD3 þ lymphocytes were markedly decreased in FASST
skin (Fig. 1h). Increases in myeloid cells and concurrent decreases
in lymphocytes can be indicative of an immunosuppressive
environment.
Senescent stroma increases CD11b þ Ly6GHi and Treg cells. To
elucidate how senescent stromal cells alter inﬂammation, we
interrogated the identity of the various cell lineages recruited to a
senescent microenvironment. To provide a tractable model, we
isolated MSFs from FASST mice and induced them to senesce
in vitro by the addition of TAM. We then used additional
markers including MHCII, F4/80, Ly6C, CD11c, CD49b, Ly6G,
CD4 and CD8, to identify macrophages, dendritic cells, natural
killer (NK) cells, granulocytes and CD4 þ and CD8 þ T-cell
subsets. As expected, TAM treatment led to the induction of
transgene expression (GFP þ ), growth arrest, increases in
SA-bgal þ cells, increased expression of the canonical SASPfactor IL-6, and elevated expression of ﬁbroblast activation
protein (FAP), indicating they are activated stromal cells
(Fig. 2a–e and Supplementary Fig. 3a–c). Further, as would be
expected by our GSEA analysis (Supplementary Fig. 2a),
senescent MSFs displayed increased levels of p-STAT3
(Supplementary Fig. 3d,e). To determine how senescent MSFs
inﬂuenced the host immune response, we injected senescent or
non-senescent MSFs subcutaneously into syngeneic, wild-type
mice. Histological analyses revealed that the tissue architecture
found at sites where matrigel alone or non-senescent MSFs were
injected was similar to the normal adjacent skin (Fig. 2f). This
ﬁnding indicates that at the time of analysis the injection itself did
not elicit an inﬂammatory response. In contrast, senescent MSFs
dramatically increased the number of inﬂammatory cells and
extracellular matrix deposition (Fig. 2f). While senescent tumour
cells are reportedly cleared from tissues by the immune system26,
GFP þ , IL-6-expressing senescent MSFs persisted within
senescent isografts (Fig. 2f and Supplementary Fig. 3f–h),
indicating that the senescent MSFs were not cleared by the
immune system. Subsequent immunoﬂuorescence (IF) staining
revealed that the presence of senescent MSFs led to a 4.3-fold
increase in CD11b þ myeloid cells (Fig. 2g,i). This ﬁnding is
consistent with increases seen in the FASST mouse skin (Fig. 1h).
Additionally, Gr-1 þ myeloid cells were signiﬁcantly elevated by
4

3.1-fold in senescent compared with non-senescent isografts
(Fig. 2h,j). These data suggest that senescent stromal cells increase
inﬂammation characterized by myeloid cell inﬁltration.
We next used ﬂow cytometry to deﬁne the immune cell
types present within the senescent microenvironment. We
disaggregated isografts containing MSFs and stained the cells
with antibodies against immune cell markers (gating strategy
Supplementary Fig. 4a). We conﬁrmed that senescent MSFs
signiﬁcantly increased the numbers of CD11b þ myeloid cells
(data not shown). This is consistent with the staining shown in
Fig. 2g and FASST mouse skin staining shown in Fig. 1h.
Further, these CD11b þ cells expressed low levels of MHCII and
high levels of Ly6G (CD11b þ Ly6GHi) (Fig. 3a,b). No changes
were observed in the CD11b þ MHCIILoLy6CHi population
(CD11b þ Ly6CHi) (Fig. 3a–c). Analysis of cell number revealed
CD11b þ Ly6GHi cells were 2.7-fold greater in number in the
presence of senescent compared with non-senescent MSFs
(Fig. 3c). Importantly, immunoﬂuorescent staining (IF) staining
of FASST skin, where activation of senescence is mosaic in nature,
demonstrated a consistent increase in Ly6G þ cells (Fig. 3d,e).
Analysis of skin from 24-month-old mice also revealed a
signiﬁcant increase in Ly6G þ cells (Supplementary Fig. 5a,b)
coincident with increases in SA-bgal positive cells within the
stromal compartment (Supplementary Fig. 5c,d), suggesting a
naturally aging microenvironment drives increases in these cells.
Finally, lymphocyte staining of cells obtained from the isografts
resembled that found in the FASST mouse skin, showing
signiﬁcant decreases in the percentage of CD3 þ cells (Fig. 3f,
Fig. 1h). However, no signiﬁcant changes were detected for
natural killer (NK) cells, CD4 þ or CD8 þ T-cell subsets, or
CD4/CD8 T-cell ratio (Supplementary Fig. 5e–h). Using
CD11b þ MHCII þ F4/80 þ as a marker for macrophages and
CD11b þ MHCII þ F4/80-CD11c þ to identify dendritic cells, we
detected no signiﬁcant changes in the percentages of these
myeloid cells (data not shown). Together, these ﬁndings suggest
that the isograft system robustly reﬂects changes within the
FASST mouse and naturally aged skin.
CD11b þ Ly6GHi and CD11b þ Ly6CHi myeloid cells are
phenotypically consistent with granulocytic and monocytic
MDSCs and are often associated with immunosuppression27,28.
In addition, these myeloid cell subsets have been implicated in the
induction of other immunosuppressive cell types including
FOXP3 þ T regulatory cells (Treg) (refs 28,29). We noted a
signiﬁcant 2.6-fold increase in CD3 þ CD4 þ FoxP3 þ Treg cells in
senescent microenvironments (Fig. 3g,h, gating strategy
Supplementary Fig. 4b). While no changes in number or
percentage of CD4 þ T cells were detected, the increases in
FoxP3 þ cells within the CD4 þ T-cell subset is consistent with a
functional shift towards an immunosuppressive T-cell population.
In agreement with this shift, we found signiﬁcant increases in
immunosuppressive factors within senescent isografts. Indeed,
Arg1, Nos2, TGF-b and IL-10 were signiﬁcantly increased along
with other pro-inﬂammatory cytokines and chemokines including
IL-6, CCL2, GM-CSF, M-CSF, IL1-b, IL1-a and CXCL1 in the
senescent microenvironment (Fig. 3i). Further, expression of the
transcription factor STAT3 that can drive SASP expression as well
as immunosuppressive inﬂammation30, was also signiﬁcantly
increased in senescent versus non-senescent isografts (Fig. 3i).
Together these data demonstrate that the presence of senescent
stromal cells leads to the development of an immunosuppressive
microenvironment.
The increased presence of immunosuppressive cell types and
signalling molecules in the senescent microenvironment led us to
ask if senescence-derived factors were sufﬁcient to drive increases
in suppressive myeloid cells. Thus, we generated conditioned
medium (CM) from non-senescent or senescent MSFs and placed
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Figure 2 | Senescent ﬁbroblasts drive inﬂammation. (a) MSFs isolated from FASST mice show activation of the GFP transgene following addition of 10 mM
TAM. Flow cytometry plots with the percent of cells expressing GFP (lower right corner) in non-senescent (Non-Sen) and senescent (Sen) MSFs.
Representative plot. n ¼ 5. (b) Senescence-associated b-galactosidase (SA-bgal) staining (blue) on MSFs from FASST mice treated with 10 mM TAM (Sen)
or vehicle (Non-Sen). Scale bar, 100 mm. Representative images. (c) Quantiﬁcation of SA-bgal staining. Data are presented as mean percent positive
cells þ s.e.m. * indicates P value o0.05 by Student’s t-test. n ¼ 3. (d) Quantiﬁcation of secreted IL-6 protein from Sen or Non-Sen MSFs. Data represents
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*P value o0.05 by Student’s t-test. n ¼ 3. (e) IL-6 mRNA expression from MSFs (Sen or Non-Sen) measured by qRT–PCR. Graph represents mean IL-6
mRNA expression in senescent versus non-senescent MSFs. * indicates P valueo0.05 by Student’s t-test. Error bars are s.e.m. Representative experiment.
n ¼ 10. (f) H&E staining of adjacent skin, matrigel alone, non-senescent (Non-Sen) and senescent (Sen) subcutaneous isografts. Scale bar, 100 mm.
Representative images. * indicates site of zoomed images (right). Scale bar, 20 mm in the zoomed images. n ¼ 4–6. (g) IF for CD11b þ (red) cells present in
Non-Sen and Sen subcutaneous isografts. Scale bar, 100 mm. Representative images. n ¼ 3. (h) IF for Gr-1 þ (red) cells present in Non-Sen and Sen
subcutaneous isografts. Scale bar, 100 mM. Representative images. n ¼ 3. (i) Quantiﬁcation of CD11b þ cells shown in g. *indicates P value o0.05 by
Student’s t-test. Data are presented as the mean þ s.e.m. of CD11b þ cells per  20 ﬁeld of view (FOV). Representative experiment. n ¼ 3.
(j) Quantiﬁcation of Gr-1 þ cells shown in h. * indicates P value o0.05 by Student’s t-test. Data are presented as the mean þ s.e.m. of Gr-1 þ cells per
 20 FOV. Representative experiment. n ¼ 3. H&E, haematoxylin and eosin; qRT–PCR, quantitative PCR with reverse transcription.

it on naive bone marrow cells for 96 h and then stained cells with
a panel of antibodies against myeloid surface markers before ﬂow
cytometric analysis (Fig. 3j). This analysis revealed that CM from
senescent MSFs led to a 3.5-fold increase in CD11b þ Ly6GHi cells

(Fig. 3k), which is the same cell type increased in vivo in the
presence of senescent MSFs.
To determine if the increases in CD11b þ Ly6GHi and Treg cells
coincided with T-cell dysfunction, we assessed the ability of
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CD8 þ T cells to respond to stimulation. Because there were no
tumour cells and therefore no antigens present to activate
the CD8 þ T cells, we turned to a PMA (phorbol 12-myristate
13-acetate), ex vivo, stimulation approach. Following PMA
stimulation, the cells were stained with antibodies to identify
CD8 þ T cells expressing IFNg, a cytokine which promotes
increased tumour immunogenicity and often used to assess
T-cell activation31 (Fig. 4a, gating strategy Supplementary
Fig. 4c). We found that CD8 þ T cells harvested from
senescent microenvironments exhibited reduced PMAstimulated activation as evidenced by a signiﬁcant 2.2-fold
decrease in expression of IFNg compared with non-senescent
MSFs (Fig. 4b,c).
Given that senescent isografts had signiﬁcantly reduced
percentages of CD8 þ IFNg þ cells and that CM from senescent
MSFs was sufﬁcient to alter the myeloid cells derived from
naive bone marrow, we next asked if the SASP functionally
impacted these cells by performing a T-cell suppression assay.
Bone marrow-dervied myeloid cells (BMDMs) conditioned
with senescent versus non-senescent MSF CM were plated with
anti-CD3 stimulated splenocytes to assess their ability to suppress
T-cell proliferation (Fig. 4d). Strikingly, myeloid cells conditioned
with medium from senescent MSFs signiﬁcantly suppressed
CD8 þ T-cell proliferation (Fig. 4e). Thus, SASP factors secreted
by senescent stromal cells were sufﬁcient to generate myeloid
cells that potently suppress T-cell responsiveness. Given this
immunosuppressive capacity, the cells formerly identiﬁed as
CD11b þ Ly6GHi will be referred to as granulocytic MDSCs
(G-MDSCs)27,28. Collectively, increases in G-MDSCs and Treg
cells along with decreases in CD8 þ T-cell function indicate
that senescent stromal cells were sufﬁcient to create an
immunosuppressive microenvironment.

Senescent stroma limits immune surveillance. To address
whether senescent stroma drives increases in tumour growth
through the establishment of inﬂammation, we injected senescent
or non-senescent MSFs admixed with one of two different
isogenic tumour cell lines into wildtype mice. PDSC5 is a
tumour-derived murine squamous cell carcinoma cell line and
MK16-Ras is a human papilloma virus (HPV) E6/E7
immortalized murine keratinocyte cell line that was transformed
by stable transduction with H-rasv12. We found that senescent
MSFs signiﬁcantly increased the growth of each tumour cell line
compared with non-senescent MSFs. Indeed, PDSC5 and
MK16-Ras tumour cell growth was increased 2.3- and 6.9-fold,
respectively, when either was co-injected with senescent versus
non-senescent MSFs (Fig. 5a–c). This increase in growth
was independent of changes in vascularization as CD31 staining
revealed no signiﬁcant differences between senescent and
non-senescent isografts (Fig. 5d,e). Further, this was consistent
with the FASST mouse model where CD31 staining was
unchanged in FASST skin compared with littermate controls
(Supplementary Fig. 6a–c).
To determine if this increase was due to a direct effect of
senescent MSF-derived factors on tumour cells and/or input from
the immune system, we co-injected tumour cells and MSFs into
nude mice. While the tumours grew robustly in nude mice as
expected (data not shown), we were surprised to ﬁnd that the
tumour promoting activities of senescent and non-senescent
MSFs were equivalent (see hashed bars, PDSC5, P ¼ 0.24,
MK16-Ras, P ¼ 0.49 by Wald test) (Fig. 5f). These ﬁndings
deviate from previously published work14–16 and may derive
from the differences in both the SASP factors expressed and
the responding tumour cell types interrogated. Despite this
difference, these data clearly suggest that the growth promoting
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Figure 5 | Senescent stromal cells promote immune-mediated tumour growth. (a) Representative images of whole-body imaging for PDSC5 tumour
cell-ﬁbroblast co-injections day 9 post injection. Scale for photon ﬂux is shown to the right of the image. (b) Tumour growth following non-senescent
(Non-Sen) or senescent (Sen) subcutaneous co-injections with PDSC5 tumour cells. Live imaging analysis of day 9 growth is represented as MPF
(photons per second) þ s.e.m. * indicates P value o0.05 by Student’s t-test. n ¼ 8. Data shown here is derived from the same experiment shown in
Fig. 6b, thus Sen mice received IgG control antibody. (c) Tumour growth following Non-Sen or Sen subcutaneous co-injections with MK16-Ras tumour
cells. Caliper measurements were performed on day 26 following injection. * indicates P value o0.05 by Student’s t-test. Data are presented as mean tumour
area (mm2) þ s.e.m. n ¼ 8–9. (d) IF CD31 (red) staining Sen versus Non-Sen subcutaneous PDSC5 tumour co-injections. Scale bar, 100 mM. Representative
images. (e) Quantiﬁcation of CD31 IF staining shown in f. ns is not signiﬁcant by Student’s t-test. Data are presented as the MFI þ s.e.m. per  20 FOV. n ¼ 7–
8. FOV, ﬁeld of view. MPF, mean photon ﬂux. (f) Tumour growth following subcutaneous co-injections with PDSC5 (left) or MK16-Ras (right) tumour cells into
immune-deﬁcient, nude mice (striped bars) or immune-competent, wild-type mice (solid bars). Data represents the fold growth of Sen co-injections over
non-Sen co-injections within each mouse strain. * indicates P value o0.05 by Wald test. ns is not signiﬁcant. Data are presented as mean fold growth þ s.e.m.
n ¼ 6–10 for immune-deﬁcient mice. n ¼ 6–19 for immune-competent mice. Senescent cells signiﬁcantly stimulated tumour growth in wild-type mice
but failed to do so in nude mice. (g) Flow cytometry analysis of isografts containing PDSC5 tumour cells and non-Sen or Sen-MSFs. Data represents
the mean CD11b þ Ly6GHi cell number per mouse þ s.e.m., 4 days following co-injection. * indicates P value o0.05 by Student’s t-test. n ¼ 4.

effects of senescent ﬁbroblasts in immune competent mice are
derived from their ability to manipulate the immune system to
favour tumour cell growth. In support of this hypothesis, we
found that within tumours CD11b þ Ly6GHi cells were increased
when tumour cells were co-injected with senescent MSFs versus
non-senescent MSFs (Fig. 5g).
Senescent stroma establishes a tumour permissive environment.
Senescent stromal-derived SASP is sufﬁcient to generate increases
in G-MDSCs that limit T-cell function (Fig. 4e). To determine if
the G-MDSC population was actively limiting T-cell responses and
promoting tumour growth in senescent microenvironments, we
8

used a Ly6G neutralizing antibody (aLy6G, clone 1A8) to deplete
G-MDSCs (our depletion approach efﬁciently eliminated greater
than 85% of these cells (data not shown)) and co-injected
senescent MSFs and PDSC5 or MK16-Ras cells. We found that the
depletion of Ly6G þ cells signiﬁcantly reduced the ability of
senescent MSFs to promote the growth of both MK16-Ras
and PDSC5 tumour cells (Fig. 6a–c). Thus, G-MDSCs are a
critical mediator of senescent stromal-driven tumour promotion.
In addition, using a neutralizing antibody against CD8a, we tested
the consequences of a cytotoxic T lymphocyte (CTL) response
on tumour growth. Upon CTL depletion, tumour growth within a
non-senescent microenvironment mimicked the growth observed
in a senescent microenvironment (Fig. 6d). Importantly, the
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growth in Non-Sen or Sen subcutaneous co-injections with PDSC5 tumour cells. Mice were treated I.P. with a neutralizing Ly6G antibody (or control IgG)
every 3 days. Live imaging analysis of day 9 growth is represented as MPF þ s.e.m. *P value o0.05, Student’s t-test. n ¼ 7–8. (c) Effect of Ly6G þ cell
depletion on tumour growth in Non-Sen or Sen subcutaneous co-injections with MK16-Ras tumour cells. Mice were treated I.P. with a neutralizing Ly6G
antibody (or control IgG) every 3 days. Data are presented as mean tumour area (mm2) þ s.e.m. at day 26 post injection. *P value o0.05, Student’s t-test.
n ¼ 14–18. (d) Effect of CD8 depletion on tumour growth in Non-Sen or Sen subcutaneous co-injections with PDSC5 tumour cells. Mice were treated I.P. with
a neutralizing CD8 antibody (or control IgG) twice weekly. Tumour growth was assessed by live imaging analysis. Data are presented as mean fold
growth þ s.e.m. *P valueo0.05, Student’s t-test. ns is not signiﬁcant. n ¼ 9–10. (e) CD8 þ and Ly6G þ cell depletion in mice bearing PDSC5 tumour coinjections. Mice were treated I.P. with one out of three dosing regimens: IgG, aLy6G or aCD8 þ aLy6G. aCD8 was given twice weekly and aLy6G was given
every 3 days for the duration of the experiment. Mice were subcutaneously injected with Non-Sen þ PDSC5 or Sen þ PDSC5 and tumour growth was
assessed by live imaging analysis. Data are presented by mean fold growth þ s.e.m. *P valueo0.05, Student’s t-test. ns is not signiﬁcant. n ¼ 5–10. MPF, mean
photon ﬂux.

senescent microenvironment showed no signiﬁcant change in
tumour growth following CTL depletion consistent with a microenvironment devoid of anti-tumour T-cell activity (Fig. 6d).
To determine if G-MDSCs exerted their pro-tumorigenic
activity by limiting CTL responses, we performed depletion
studies targeting both G-MDSCs and CTLs. Mice were treated
with control antibody (IgG), Ly6G neutralizing antibody
(aLy6G), or both aLy6G and aCD8. Following depletion, mice
were injected with non-senescent or senescent MSFs and PDSC5
tumour cells and tumour growth was assessed. As expected, we
found that in non-senescent microenvironments, depletion of
Ly6G þ cells had no effect on tumour cell growth while
co-depletion of CTLs led to signiﬁcant increases in tumour cell
growth when compared with control antibody (Fig. 6e). Together
these data demonstrate that in the presence of non-senescent
MSFs, a potent CTL response limits tumour cell growth. In

contrast, in the presence of senescent MSFs where we ﬁnd
increases in G-MDSCs and reduced CTL activation (Figs 3b,c and
4c–e), depletion of Ly6G þ cells resulted in signiﬁcant reductions
in tumour cell growth (Fig. 6b,c,e). To establish that G-MDSCs
actively limit an effective CTL response, we depleted both CD8 þ
and Ly6G þ cells from mice injected with senescent MSFs and
tumour cells. Strikingly, we found that simultaneous depletion of
CD8 þ and Ly6G þ cells restored the increased tumour growth
observed in the presence of senescent MSFs (Fig. 6e). These
results show that senescent stromal cells mediate tumour cell
growth by actively inhibiting anti-tumour CTL responses.
SASP-derived IL-6 promotes a suppressive environment.
Senescent MSFs express a large cadre of inﬂammatory SASP
factors, including IL-6 which is the most highly upregulated
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were signiﬁcantly reduced (Fig. 7b), indicating that IL-6 is
important for their accumulation in the presence of senescent
MSFs.
To establish that senescent-derived IL-6 was necessary to drive
the emergence of MDSCs, we carried out a T-cell suppression
assay using BMDMs conditioned with medium from senescent
cells following IL-6 neutralization. As expected, cells grown in
senescent CM neutralized of IL-6 failed to suppress T-cell
proliferation to the same degree as control IgG-treated senescent
CM (Fig. 7c). Together these data demonstrate an integral role
for senescent stromal-derived IL-6 in the establishment of
immunosuppressed microenvironments.
To test whether senescence-derived IL-6 promotes tumour cell
growth through MDSCs accumulation, we co-injected tumour
cells with non-senescent or senescent MSFs into mice that were
treated with an IL-6 neutralizing antibody. We found that IL-6
neutralization led to a signiﬁcant decrease in PDSC5 and
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factor in both our MSF gene expression analysis and in vivo in the
isograft gene expression proﬁle (Figs 1c, 3i and Supplementary
Fig. 2b). While many of the SASP factors could inﬂuence the
immune response, we chose to focus on the role IL-6 might play
because it has been shown to affect myeloid cell function. Indeed,
IL-6 can collaborate with GM-CSF to induce suppressive myeloid
cells from naive bone marrow in mice and from peripheral blood
mononuclear cells in humans32,33. In addition, IF staining in
FASST mouse skin shows signiﬁcant increases in stromal IL-6
(Supplementary Fig. 7a,b). Thus, to determine if stromal-derived
IL-6 plays a role in the inﬂammatory phenotypes we observed in
senescent microenvironments, we depleted it in vivo. Senescent or
non-senescent MSFs were subcutaneously injected into control or
IL-6-depleted mice. In mice harbouring senescent MSFs,
depletion of IL-6 reduced G-MDSCs to levels observed in mice
bearing non-senescent MSFs (Fig. 7a). Consistent with the in vivo
results, when IL-6 was neutralized in senescent CM, G-MDSCs
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Figure 7 | IL-6 within senescent microenvironments mediates immunosuppression and tumour promotion. (a) Flow cytometry for G-MDSC following
IL-6 depletion in non-senescent (Non-Sen) or senescent (Sen) isografts. *P value o0.05, Student’s t-test. ns is non-signiﬁcant. Data are mean % of
CD45 þ population þ s.e.m. n ¼ 3–7. (b) Flow cytotmetry of bone marrow cells treated with CM depleted of IL-6. Set-up shown in Fig. 3j. *P value o0.05,
Student’s t-test. ns is not signiﬁcant. Data are mean # of cells per plate þ s.e.m. n ¼ 4. (c) T-cell suppression assay following IL-6 depletion. Set-up shown in
Fig. 4d. Bone marrow cells were conditioned with Sen þ IgG (Sen), Sen þ aIL6 or control (CTR) medium. *P value o0.05, by analysis of variance. Data are
mean % proliferation þ s.d. of triplicates. n ¼ 3. (d) Imaging following IL-6 depletion in PDSC5 tumour co-injections. Non-Sen with PDSC5 (Non-Sen),
Sen þ IgG with PDSC5 (Sen) and Sen þ aIL6 with PDSC5 on day 9 post injection. (e) PDSC5 tumour growth in IL-6 depleted Non-Sen and Sen isografts.
Data are represented as MPF (photons per second) þ s.e.m. *P-valueo0.05, Student’s t-test. ns is not signiﬁcant. n ¼ 10. (f) MK16-Ras tumour growth in
IL-6-depleted Non-Sen and Sen isografts. *P value o0.05, Student’s t-test. ns is not signiﬁcant. Data are mean tumour area (mm2) þ s.e.m. n ¼ 7–22.
(g) Depletion of IL-6 has no direct effect on PDSC5 tumour growth when stromal cells are not present. Data are MPF þ s.e.m. ns is not signiﬁcant,
PZ0.05, Student’s t-test. n ¼ 8–10. (h) Depletion of IL-6 has no direct effect on MK16-Ras tumour growth when stromal cells are not present. Data are
mean tumour area (mm2) þ s.e.m. ns is not signiﬁcant, PZ0.05, Student’s t-test. n ¼ 13–15. (i) IL-6 neutralization does not impact in vitro tumour cell
growth. Sen CM depleted of IL-6 or treated with IgG do not differentially impact PDSC5 or MK16-Ras growth. Data are mean fold growth þ s.e.m. ns is not
signiﬁcant, Student’s t-test. n ¼ 6. MPF, mean photon ﬂux.
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MK16-Ras tumour cell growth relative to control IgG (1.8- and
1.9-fold, respectively) (Fig. 7d–f). Importantly, IL-6 neutralization
had no effect when tumour cells were injected alone (Fig. 7g,h).
Further, IL-6 neutralization of senescent CM failed to impact the
in vitro growth of tumour cells alone (Fig. 7i). Together, these
ﬁndings suggest that senescent stromal-derived IL-6 promotes
tumour growth by driving accumulation of G-MDSCs.
To establish that the source of IL-6 was indeed senescent
stromal cells and not another cell type within the microenvironment, we engineered two different IL-6-targeting short
hairpin MSF cell lines. When control shRFP-expressing MSFs
were induced to senesce, they stained positive for SA-bgal,
expressed increased levels of IL-6, (Fig. 8a–e) and upon
co-injection with PDSC5 tumour cells, promoted tumour cell
growth 3.2-fold compared with non-senescent, shRFP-expressing
MSFs (Fig. 8f). In contrast, the senescent shIL-6 MSF lines, which
expressed signiﬁcantly reduced levels of IL-6 (Fig. 8e), failed to
promote tumour cell growth compared with non-senescent MSFs
expressing the same hairpins (Fig. 8f). This lack of growth
promotion corresponded to the degree of IL-6 knockdown in the
individual cell lines with shIL6 #1 showing the greatest degree of
Non-Sen

Sen

d

Senescence-associated inﬂammation increases in human skin.
Senescent cells increase in many tissues including the skin of
humans as they age7. In addition, recent evidence shows that
suppressive myeloid cells increase with age in the circulation of
humans and are elevated within the spleens of older mice6,34,35.
However, whether the accumulation of suppressive myeloid cells
within senescent tissues of older individuals can precede the
appearance of a tumour remains an open question. To identify
senescent cells within human skin, we turned to the well-
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IL-6 knockdown (Fig. 8e) and the greatest reduction of tumour
growth promotion compared with the control shRFP line
(Fig. 8f). Importantly, when the inﬂammatory inﬁltrate was
proﬁled, the presence of control senescent shRFP-expressing
MSFs led to increases in G-MDSCs while shIL6-expressing
senescent MSFs failed to enrich for this population (Fig. 8g) even
in the presence of tumour cells (Fig. 8h). Together these data
indicate that senescent stromal-derived IL-6 plays a key role in
the establishment of an environment that potently inhibits T-cell
function through G-MDSCs.
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Figure 8 | Senescence-derived IL-6 is necessary to drive G-MDSC accumulation and tumour promotion. (a) Senescence-associated b-galactosidase
(SA-bgal) staining (blue) of shRFP-expressing MSFs treated with 10 mM TAM (Sen) or vehicle (Non-Sen) revealed B65% of cells were senescent
following TAM treatment. Scale bar, 100 mm. n ¼ 3. (b) SA-bgal staining (blue) of shIL6#1-expressing MSFs treated with 10 mM TAM (Sen) or vehicle
(Non-Sen) revealed B55% of shIL6 #1 cells were senescent following TAM treatment. Scale bar, 100 mm. n ¼ 3. (c) SA-bgal staining (blue) of shIL6#2expressing MSFs treated with 10 mM TAM (Sen) or vehicle (Non-Sen) revealed B55% of shIL6 #2 cells were senescent following TAM treatment. Scale
bar, 100 mm. n ¼ 3. (d) Quantiﬁcation of SA-bgal-positive shRFP-, shIL6 #1-, and shIL6 #2-expressing cells shown in a–c. Data are mean %-positive
cells þ s.e.m. *P value o0.05, Student’s t-test. n ¼ 3. (e) qRT–PCR for IL-6 mRNA expression. Data are relative IL-6 mRNA in Sen/Non-Sen shIL6 lines
compared with shRFP. n ¼ 3. Representative experiment. (f) Impact of senescent stromal-derived IL-6 on tumour growth. MSFs expressing IL-6-speciﬁc
hairpins (shIL6 #1 or shIL6 #2) were co-injected with PDSC5 tumour cells. shRFP was used as a control. Data are mean fold growth of Sen co-injections
over Non-Sen co-injections þ s.e.m. Non-Sen injections are normalized to 1. *P value o0.05, Wald test. ns is not signiﬁcant. n ¼ 5–10. (g) Flow cytometry of
shRFP or shIL6 #1-expressing Non-Sen or Sen MSF isografts. Mice were injected with senescent or non-senescent MSFs that expressed a control shRFP or
were depleted of IL-6 through the expression of the shIL6 #1 short hairpin. Data represents the mean number of G-MDSCs þ s.e.m., per mouse. *P value
o0.05, Student’s t-test. ns is not signiﬁcant. n ¼ 3–4. (h) Flow cytometry of shIL6 expressing Non-Sen or Sen MSF-PDSC5 co-injections. Mice were
injected with PDSC5 tumour cells and senescent or non-senescent MSFs depleted of IL-6 through the expression of shIL6 #1. Data represents the mean
number of G-MDSCs þ s.e.m., per mouse. ns is not signiﬁcant, Student’s t-test. n ¼ 3–4. qRT–PCR, quantitative PCR with reverse transcription.
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that corresponded with a 3.5-fold increase in CD45 þ cells
(green) (Fig. 9c,d) compared with skin from younger individuals
aged 29–32 years. Additionally, using IL-6 (red)/p16 (green)
co-staining we provide evidence that senescent cells within
human tissue express the important inﬂammatory mediator IL-6,
which can also serves as a surrogate for SASP expression.
We detected p16 þ IL-6 þ cells in the older (age 63–73) cohort of
donors as well as signiﬁcant increases in IL-6 within the stromal
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characterized senescence maker p16INK4a (p16), which is used
extensively in human tissue23,36. We co-stained normal human
skin of varying age with antibodies against p16 (red) and CD45
(green) to identify senescent cells and leukocytes, respectively.
Our staining approach revealed a pattern that was consistent with
that observed in the FASST mouse model. Intriguingly, we found
that the skin from older individuals aged 63–73 years had a
4.3-fold increase in senescent cells within the stroma (Fig. 9a,b)
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Figure 9 | Increases in senescent stromal cells in aged human skin correlate with increases in inﬂammation. (a) IF staining for p16INK4a (red) in human
skin samples grouped by age. Nuclei are DAPI-stained (blue). Scale bar, 100 or 10 mm in zoomed inset image. *site of zoomed image. (b) Quantiﬁcation of
p16INK4a (red) staining shown in a. grouped by age. *P value o0.05, Student’s t-test. Data are mean þ s.e.m. Graph contains data from four donors per age
group, multiple images (5–17) per donor. (c) IF staining for CD45 (green) in human skin samples grouped by age. Nuclei are DAPI-stained (blue). Scale bar,
100 or 10 mm in zoomed inset image. *site of zoomed image. (d) Quantiﬁcation of CD45 (green) staining shown in c. grouped by age. *P value o0.05,
Student’s t-test. Data are mean þ s.e.m. Graph contains data from four donors per age group, multiple images (5–17) per patient. (e) IF staining for
p16INK4A (p16, green) and IL-6 (red) on human skin. Nuclei are DAPI-stained (blue). Secondary alone control showed no detectable staining (data not
shown). Double-positive staining (yellow) was noted in older individuals (Age 63–73). Scale bar, 100 mm. (f) Quantiﬁcation of IL-6 IF staining shown in
e. Data are the MFI þ s.e.m. per  20 FOV. *P value o0.05, Student’s t-test. Four donors per age group, multiple images (4–10) per donor were analysed.
(g) IF co-staining for p16INK4a (red) and CD45 (green) in human skin. Nuclei are DAPI-stained (blue). Panel e is the merged image of the staining shown in
a,c. Scale bar, 100 or 10 mm in zoomed inset image. *site of zoomed image. (h) Images from staining shown in e were analysed using the same spatial
statistics described in Fig. 1g. In samples from donors aged 63–73, a strong association of p16 þ and CD45 þ cells was observed (mean normalization score
2.9, 95% CI 2.4–3.4). Samples from donors aged 29–32 show weak association (mean normalization score 0.8, 95% CI 0.2–1.4). 4 patients per age group.
Error bars are s.d. n ¼ 27–37. FOV, ﬁeld of view.
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compartment (Fig. 9e,f). These ﬁnding demonstrate that within
aging human skin, senescent stromal cells express IL-6 and may
affect local inﬂammation.
We next determined whether the presence of senescent stromal
cells correlated with changes in immune localization within
human skin. Thus, we returned to p16 and CD45 co-staining and
performed the same non-biased spatial analysis previously used in
the FASST mouse skin (Fig. 1f,g). Strikingly, our spatial analysis
from individuals aged 63–73 years revealed a clear preferential
localization of CD45 þ cells near p16 þ senescent stromal cells
(values40) reminiscent of that observed in the skin of FASST
mice (Fig. 9g,h). This strong preferential localization was not
observed in the younger individuals (Fig. 9h). This ﬁnding
suggested that within aging human skin, senescent stromal cells
reshape the local immune landscape.
We next sought to determine if the CD45 þ cells observed
within the skin of older individuals expressed cell surface markers
consistent with immunosuppressive cell types. CD33 marks
human cells analogous to MDSCs found in mice37. IHC staining
for CD33 revealed a marked increase in CD33 þ cells in the older
age grouping compared with the younger (Fig. 10a,b). The cell
surface proteins CD15 and CD14 can be used to further identify
granulocytic and monocytic cells, respectively37. Further staining
indicated that cells positive for CD15 were also increased in
the skin of older individuals, as were CD14 þ cells (Fig. 10c–f).
Importantly, these normal skin samples had no detectable
hyperplasia or neoplasia that could explain the increased
presence of CD33 þ MDSCs. Thus, these data taken together
suggest that senescent cells within older individuals may drive the
development of inﬂammatory microenvironments that shelter
incipient tumour cells from effective CTL detection and
elimination (Fig. 10g).
Discussion
Senescence plays an important role in biological processes
ranging from patterning in developing embryos and wound
healing, to tumour prevention and tumour promotion38–44.
The mechanisms responsible for the paradoxical role that
senescence plays in tumorigenesis have remained obscure but
are likely to lie in the senescent secretory proﬁle that is deﬁned by
the cell of origin11. While a recently published report has
implicated transformed senescent cells in the establishment of
immunosuppression30, our work is the ﬁrst to identify senescence
as a driver of immunosuppression distinct from the role played by
tumorigenic cells. In our work, we found that the stromal-derived
SASP-factor IL-6 establishes myeloid-driven immunosuppression
where CD8 þ T cells were inhibited, resulting in unrestrained
tumour growth. Importantly, senescent stromal cells were
sufﬁcient to drive these changes. This phenotype is in contrast
to the anti-tumorigenic role senescence plays when it arises in
tumour cells13,45. In addition to directly limiting replicative
capacity, in this setting the secretion of inﬂammatory cytokines
can elicit immune-mediated clearance of senescent tumour
cells46. Indeed, the immune-mediated clearance of senescent
tumour cells has been documented in several settings. Xue et al.
demonstrated that within the liver, senescent carcinoma cells
elicited immune-mediated clearance that restrained tumour
growth13. In contrast, in an obese setting, senescent liver
stellate cells drove promotion of liver carcinomas47. Conversely,
senescence within premalignant hepatocytes induced CD4 þ
T-cell-mediated clearance and thus limited liver cancer
development45. In a PTEN-null, prostate cancer model, again
robust induction of senescence was observed within tumour cells
throughout the tissue30. However, these cells were not cleared,
suggesting that clearance of senescent cells may be tissue-speciﬁc,

cell type-speciﬁc and/or speciﬁc to the mutational proﬁle of the
transformed cells in question.
Despite the tumour suppressive role senescence plays when it
arises within incipient tumour cells, a recent study demonstrated
that senescence represents an important tumour-promoting
mechanism in aging animals. In this study, it was shown that
the elimination of senescent cells within an aging mouse decreased
life long tumour rates10. Our work provides a possible mechanism
to describe these ﬁndings. Indeed we demonstrate that senescent
stromal cells create an immunosuppressive environment
characterized by the accumulation of MDSCs that limit CD8 þ
T-cell responses and allow tumour cell growth.
To date, investigation into the mechanisms that drive MDSC
recruitment to a premalignant or malignant tissue has been
restricted to determining how tumour cells (or premalignant
cells) achieve this. Our model is distinct because it demonstrates
that age-related changes in the stromal compartment that
arise in the absence of premalignant and malignant cells are
sufﬁcient to drive the recruitment of suppressive cells. Because
the presence of senescent stromal cells correlates with increases in
MDSCs in aged human skin, our ﬁndings suggest that senescent
stromal cells provide a safe harbour for emerging neoplastic
clones. Indeed, it is possible that the genesis of many tumours lies
in the creation of a perfect storm where initiated tumour cell
clones arise within the immunosuppressive sphere of senescent
stromal cells. As such, our ﬁndings raise the possibility that
senescent stromal cells represent an important preventative
target.
While our model is representative of the stromal compartment
of aged tissue (Fig. 9) and shows that senescent stromal cells can
recruit suppressive cells that support tumour formation, it raises
the question, do all senescence inducers within the stromal
compartment induce similar changes? In fact it is unlikely that all
inducers of senescence invoke identical immune changes. For
example, Campisi and colleagues have shown that unlike
chronologically, ARF, or Ras-induced senescence, p16-induced
senescence does not lead to SASP expression48. Thus, one might
expect that p16-induced senescence would not impact the local
immune response as we have described for p27-induced
senescence, which induces a SASP reminiscent of that observed
in ﬁbroblasts undergoing chronologic aging11. Finally, it will be
important that future studies test the impact of senescent stromal
cells in a spontaneous tumour model. While our isograft model
was an important tool to understand how senescent ﬁbroblasts
can induce local immune changes, the real challenge will be to
incorporate these ﬁndings into a spontaneous model where
senescent ﬁbroblasts arise in the direct vicinity of initiated,
preneoplastic cells. The challenge now lies in the design of an
inducible model that maintains the mosaic activation of
senescence in the stromal compartment reminiscent of what we
(Fig. 9) and others7 have reported in human tissue and the
simultaneous induction of initiating mutations in the direct
vicinity of senescent stromal cells and their associated immune
changes. Such models await the development of stromal speciﬁc
inducible alleles that can be combined with inducible tumour
initiating epithelial alleles. Such models will be critical for the
future development of multi-pronged cancer therapy.
Methods
Mice. Wildtype FVB, female mice age 6–8 weeks were used in all subcutaneous
injection and co-injection experiments unless otherwise noted. For naturally aged
mouse experiments, 24-month-old and 2-month-old, wild-type, female Balb/c mice
were obtained from the National Institute of Aging. All mice were used in compliance with the Washington University Institutional Animal Care and Use
Committee under protocol #20130196.
To obtained stromal-speciﬁc activation of a lox-stop-lox cassette mice
expressing a chimaeric gene encoding the Cre-ERT2 fusion protein, which allows
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Figure 10 | Immunosuppressive cell types are enriched in aged human skin. (a) Representative IHC staining for CD33 in human skin grouped by age.
Scale bar, 100 mm. (b) Quantiﬁcation of CD33 IHC staining in human skin grouped by age. * indicates P value o0.05 by Wald test. Data are presented as
mean CD33 þ cells per  20 FOV þs.e.m. Data represents four donors per age group, multiple images (5–27) per donor were used for quantiﬁcation.
(c) Representative human IHC staining for CD15 grouped by age. Scale bar, 100 or 10 mm for zoomed inset image. * indicates location of zoomed image.
(d) Quantiﬁcation of CD15 IHC staining in human skin grouped by age. * indicates P value o0.05 by Wald test. Data are presented as mean CD15 þ cells
per  20 FOV þs.e.m. Graph is of four donors per age group, multiple images (2–15) per donor were used for quantiﬁcation. (e) Representative human IHC
staining for CD14 grouped by age. Scale bar, 100 mm. (f) Quantiﬁcation of CD14 IHC staining in human skin grouped by age. * indicates P valueo0.05 by
Wald test. Data are presented as mean CD14 þ cells per  20 FOV þs.e.m. Graph is of four donors per age group, multiple images (5–22) per donor were
used for quantiﬁcation. (g) Model for SASP-driven immunosuppression resulting in age-related tumour development. Senescent stromal cells accumulate
in a mosaic fashion in aged stromal compartments in the absence of tumours. Through the SASP, senescent ﬁbroblasts are sufﬁcient to drive increases in
inﬂammation that is characterized by enrichment of MDSCs. These MDSCs suppress anti-tumour CD8 þ T-cell (CTL) responses and promote incipient
tumour outgrowth. FOV, ﬁeld of view.
for TAM-dependent recombination under the control of a mesenchymal-speciﬁc
regulatory sequence derived from the pro-alpha 2(I)collagen gene (Col-Cre-ERT2
mice, kind gift of Benoit de Crombrugghe (M.D. Anderson Cancer Center) and
Christopher Denton (Royal Free and University College Medical School) were
crossed with mice that conditionally express the cell cycle inhibitor, p27Kip1 from
the ROSA26 locus (ROSAlox-stop-lox-p27Kip1) (ref. 22). Finally, mice were subject
to speed congenics and bred to an FVB background. For transgene activation,
four-week-old FASST female mice and control littermates were given TAM
(5 mg per 10 g body weight) by intraperitoneal (IP) injection twice.
Mouse genotyping was carried out as follows: genomic DNA was extracted from
mouse tissue using the RED Extract N Amp kit (XNAT, Sigma). Primer sequences
used to determine the presence of the p27Kip1 transgene within the ROSA26 locus
were as follows: the wildtype ROSA26 locus was ampliﬁed using 30 wt: 50 -GGA
14

GCGGGAGAAATGGATATGAAGTACTGG-30 (forward) and 50 : 50 -CAAA
GTCGCTCTGAGTTGTTATCAGTAAGG-30 (reverse) and the p27Kip1 containing
locus was ampliﬁed using 30 wt: 50 -GGAGCGGGAGAAATGGATATGAA
GTACTGG-30 (forward) and 30 delta: 50 -TCCAAGAGTACTGGAAAG
ACCGCGAAGAGT-30 (reverse). Primer sequences used to amplify the Cre-ERT2
transgene were 30 : 50 -ATCCAGGTTACGGATATAGT-30 (forward) and 50 : 50 -AT
CCGAAAAGAAAACGTTGA-30 (reverse).
To amplify DNA of interest, 1 ml DNA extract was combined with 9 ml of master
mix (XNAT kit with 0.5 mM appropriate forward and reverse primers) in PCR
tubes and ampliﬁed for one cycle at 94 °C for 1 min followed by 35 cycles at
(94 °C for 30 s, 58 °C for 60 s and 72 °C for 60 s) and a 4 °C hold. PCR products
were resolved on a 1% agarose/TAE (Fisher Scientiﬁc) containing 0.002% SyberSafe
(UV gel stain, Invitrogen) gel at 100 volts for 45 min, and visualized with UV light.
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Cell lines and conditioned media treatments. The MSF cell line was isolated by
removing the dorsal skin from a female FASST mouse. The tissue was minced, then
transferred to a conical tube containing collagenase solution (2 mg ml  1
Collagenase A, 1 mg ml  1 hyaluronidase, 2 U ml  1 DNase I in serum-free
DMEM). The skin was digested at 37 °C on a rotisserie for 4 h. Following digestion,
the cells were plated and 24 h later the non-adherent cells were removed.
The PDSC5 cell line was a kind gift from Dr Lisa Coussens (Oregon Health
Science University) and was stably transduced with click-beetle red (CBR)
luciferase. MK16 cells are a primary mouse keratinocyte cell line immortalized with
HPV E6/E7 and were a kind gift from Dr Craig Woodworth, Clarkson University.
The MK16 cells were stably transduced with H-Rasv12 and CBR to generate the
MK16-Ras cell line. All cell lines were regularly tested for mycoplasma but were not
authenticated.
To induce senescence in vitro, MSFs were treated with 10 mM TAM for 48 h.
Control MSFs were treated with ethanol as vehicle. Upon treatment, cells were
moved to a modular incubation chamber and cultured at 37 °C in 3% oxygen, 5%
carbon dioxide, balanced with nitrogen.
Conditioned media (CM) was generated using MSFs isolated from FASST mice
as described. The MSFs were induced to senesce as described. At day 9, CM was
generated by washing the plates and placing serum-free medium (RPMI 1640 þ 1%
penicillin/streptomycin) onto conﬂuent plates of control or senescent MSFs.
The medium was collected after 24 h.
IL-6 neutralization of CM was performed by the use of an IL-6 neutralizing
antibody. Following collection of the CM from senescent or control MSF cells, IL-6
neutralizing antibody or IgG control antibody was added to the CM at a
concentration of 5 mg ml  1.
Plasmids and virus production. The RNAi constructs were generated by cloning
IL-6 hairpins into a pLKO.1-hygromycin plasmid using the Age1 and EcoR1
sites. The following are sequences for the RNAi constructs targeting IL-6 or a nontargeting control (shRFP): pLKO.1-shRFP-hygro 50 -CTCAGTTCCAGTAC
GGCTCCA-30 , pLKO.1-shIL6 #1-hygro 50 -GCAATGGCAATTCTGATTGTA-30 ,
pLKO.1-shIL6 #2-hygro 50 -CCAATGCTCTCCTAACAGATA-30 . MSCV-CreERT2-puro was obtained from Dr Emily Cheng (Memorial Sloan-Kettering).
PDSC5 and MK16-Ras tumour lines were transduced with pBabe-Click-Beetle Red
(CBR)-hygro and pBabe-H-rasV12-puro was stably transduced into MK16 keratinocytes to fully transform the cells and create the MK16-Ras line. The lentivirus
production and infections were carried as described49.
SA-b-gal staining. SA-bgal staining in the skin of mice was performed on frozen
sections that were ﬁxed in 0.2% glutaraldehyde for 10 min. at 4 °C. Slides were
washed in PBS and then submerged in X-gal solution (1 mg ml  1 5-Bromo-4chloro-3-indolyl b-D-galactopyranoside, 150 mM NaCl, 2 mM MgCl2, 5 mM
K3Fe(CN)6, 5 mM K4Fe(CN)6, 40 mM NaPi pH 6.0, in H20). The X-gal solution
was passed through a 0.45 mm ﬁlter before use to remove particulate. Slides were
kept at 37 °C in the dark until the stain developed (B6 h). After staining, the slides
were ﬁxed for 10 min in 0.2% glutaraldehyde at room temperature, washed in PBS
and then the nuclei were counterstained using Nuclear Fast Red (Sigma)49.
Quantitative PCR. RNA was isolated using an RNeasy isolation kit (Qiagen) and
cDNA synthesis was performed using SuperScriptII reverse transcriptase (Invitrogen).
Quantitative PCR was performed using Taqman probe/primer sets to amplify the
following genes: GAPDH (Mm99999915_g1), IL-6 (Mm00446190_m1), CXCL5
(Mm00436451_g1), CXCL1 (Mm04207460_m1), CCL2 (Mm00441242_m1), CCL5
(Mm01302427_m1), CCL8 (Mm01297183_m1), CCL7 (Mm00443113_m1) and
CXCL14 (Mm00444699_m1) (Thermo Fisher). For experiments using isograft tissue
for gene expression analysis, isografts were isolated at 11 days post injection. The
tissue was snap-frozen and then pulverized using a mortar and pestle. RNA isolation
and cDNA synthesis was performed as above. The samples were then pre-ampliﬁed
using Taqman PreAmp Master Mix kit and Taqman primers for the following genes
of interest: GAPDH (Mm99999915_g1), STAT3 (Mm01219775_m1), Nos2
(Mm00440502_m1), Arg1 (Mm00475988_m1), CXCL1 (Mm04207460_m1), M-CSF
(Mm00432686_m1), GM-CSF (Mm01290062_m1), IL-6 (Mm00446190_m1), CCL2
(Mm00441242_m1), TGFb (Mm01178820_m1), IL-1b (Mm00434228_m1), IL-1a
(Mm00439620_m1) and IL-10 (Mm01288386_m1) (Thermo Fisher). All primer
sequences are proprietary. For analysis, values are normalized to GAPDH.
RNA-sequence (RNA-seq) analysis. RNA-seq reads were mapped to the mouse
genome (mm9) using TopHat50. Mapped reads were assigned to RefSeq annotated
genes using htseq-count (http://www-huber.embl.de/users/anders/HTSeq/doc/
count.html). Differential expression was assessed using edgeR with TMM
normalization51. Log2 fold changes were computed after applying a ﬂoor of
1 c.p.m. to ensure that genes with very low over all expression, but large relative
fold changes did not affect the analysis.
Gene set enrichment analysis was performed as in using the log2 fold-change to
rank genes. P-values are those reported from GSEA for the enrichment of factors in
the JAK-STAT pathway.

Enzyme-linked immunoSorbent assay (ELISA). The protein level of IL-6
was detected in CM from non-senescent and senescent MSFs using a highsensitivity ELISA kit (eBioscience) according to manufacturer’s instructions
(cat. # BMS603HS). CM was generated as stated above.
Growth curve. Vehicle- or TAM-treated MSFs were plated on day 8 following
TAM removal. Cells were plated at a concentration of 20,000 cells/well in six-well
plates with each day plated in triplicate. Cells were lifted with trypsin and counted
using a hemocytometer daily for the four days immediately following plating.
A two-factor analysis of variance with Bonferroni’s multiple comparisons post test
was used to calculate statistical signiﬁcance among groups. Data shown are
representative of two independent experiments and presented as mean ± s.e.m.
Immunohistochemistry and immunoﬂuorescence staining. FASST mouse skin
was stained as follows: CD45, IHC staining, was carried out on formalin-ﬁxed,
parafﬁn embedded skin sections. Slides were deparafﬁnized by heating for 20 min
at 55 °C followed by submergence in a xylene bath twice for 5 min. The tissue was
then rehydrated by sequential dips into baths of decreasing ethanol concentration
going from 100% ethanol to 100% H20. Endogenous peroxidase activity was
blocked using 3% hydrogen peroxide in methanol. Following PBS wash, sections
were blocked in blocking buffer (5% normal goat serum, 2.5% BSA in PBS) in a
humidiﬁed chamber for 30 min at room temperature. Primary antibody (CD45,
1:500) was added following the blocking step. After 30 min, slides were washed in
PBS and re-blocked for 10 min in blocking buffer. A biotinylated secondary antibody was used at 1:250 for 30 min. The slides were washed in PBS and then ABCElite (Vector Labs) solution was applied for 30 min. Following PBS wash, the stain
was developed using DAB (Dako) and brieﬂy washed in water before haematoxylin
counterstain and mounting.
For CD45, GFP immunoﬂuorescent co-staining, frozen skin samples were used.
Skin samples were ﬁrst permeabilized using 0.5% Triton-X in PBS for 10 min at
room temperature. Following PBS wash, samples were blocked using Serum-free
Protein Block Solution (Dako) for 30 min. Primary antibodies, anti-CD45-PE at
1:200 or anti-IgG-PE control, and anti-GFP at 1:1,000, were then added to the skin
sections and the slides were placed in a humidiﬁed container at 4 °C overnight.
The next day, the slides were washed in PBS and secondary antibody for
detection of the unconjugated GFP antibody was added for 1 h at room
temperature. The slides were washed and subsequently mounted using ProLong
Gold with DAPI anti-fade mounting reagent (Life Technologies). Additional
information about antibodies including their catalog numbers can be found in
Supplementary Table 1.
CD31, IL-6 and Ly6G IF staining was performed on frozen FASST mouse skin
and littermate controls or 2-month and 24-month-old mice where noted. The
procedure was similar to what is detailed above for frozen section staining.
However, a primary antibody to CD31 (1:50), IL-6 (1:50) or Ly6G (1:100) were
used along with a corresponding secondary. Additional information about
antibodies can be found in Supplementary Table 1. Quantiﬁcation of staining was
performed using Fiji software to analyse mean ﬂuorescence intensity (MFI) per
image for CD31. Before calculating the MFI, the freehand selection tool was used to
select only the stromal region for MFI quantiﬁcation thus excluding the epithelium
from the analysis. Quantiﬁcation of Ly6G staining was performed using a similar
stromal selection technique.
Isograft staining was carried out as follows: formalin-ﬁxed, parafﬁn embedded
isografts were sectioned and stained. CD11b-PE (1:200) and Gr-1-PE (1:400) or as
control IgG-PE (1:200 or 1:400), immunoﬂuorescent staining was performed
using the same procedure. Slides were warmed at 55 °C for 20 min, xylene
deparafﬁnized and rehydrated as noted above for CD45 skin staining.
Antigen retrieval using citrate was performed by boiling the slides for 10 min
followed by 20 min of cooling in the citrate buffer solution. Slides were
washed in H2O and then transferred to PBS. The slides were then blocked in a
block/perm solution (3% normal goat serum, 1% BSA, 0.1% Triton-X, 0.05%
Tween-20, with Fc blocking antibody (BD Pharmingen)) at 1:200 in PBS for 2 h at
room temperature in the dark in a humidiﬁed chamber. Slides were washed in PBS
and then mounted using ProLong Gold with DAPI anti-fade mounting reagent
(Life Technologies).
GFP and IL-6 immunoﬂuorescent co-staining on frozen isograft tissues was
performed in a similar fashion to the GFP and CD45 co-staining detailed above in the
FASST skin. Brieﬂy, section were permeabilized using 0.5% Triton-X in PBS for
10 min at room temperature and blocked using Serum-free Protein Block Solution
(Dako) for 30 min. Primary antibodies, anti-GFP at 1:1,000 and anti-IL-6 at 1:50, were
then added to the skin sections for overnight incubation at 4 °C. Slides had secondary
antibody applied the next day for 1 h at room temperature. The slides were mounted
using ProLong Gold with DAPI anti-fade mounting reagent (Life Technologies).
CD31 immunoﬂuorescent staining was performed on frozen isograft tissue. The
procedure was similar to what is detailed above for FASST skin frozen section
staining. Quantiﬁcation of staining was performed using Fiji software to analyse
MFI per image. Additional information about antibodies can be found in
Supplementary Table 1.
For haematoxylin and eosin staining, slides were deparaﬁnized in three changes
of xylene then cleared in two changes of 100% EtOH. The slides were then dipped
10 times into 95% ethanol and placed in running tap water for 5 min. The slides
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were put into haematoxylin for 1 min and then under running tap water until the
water ran clear. They were then placed into 95% ethanol and subsequently stained
in eosin for 3 min. The slides were dipped ﬁve times in two changes of 95% ethanol
and then 10 times in three changes of 100% ethanol. The slides were ﬁnally dipped
10 times in three changes of xylene and mounted.
For staining of cultured ﬁbroblasts, MSFs were stained for FAP or
phosphorylated STAT3 (p-STAT3) following senescence induction. Cells were
plated on coverslips, ﬁxed in 4% paraformaldehyde for 10 min at room
temperature, washed with 1  PBS and subsequently permeabilized using 0.5%
Triton-X in PBS for 10 min at room temperature. The cells were then stained using
an anti-FAP primary antibody (1:200) or anti-p-STAT3 primary antibody (1:50)
followed by an appropriate secondary antibody. Additional information about
antibodies can be found in Supplementary Table 1.
All human samples were obtained from a retrospective study using deidentiﬁed, formalin-ﬁxed and parafﬁn-embedded human tissue specimens that
were retrieved from archived tissue bank of the Washington University
Dermatopathology Center in accordance with guidelines set by the Institutional
Review Board of Washington University (IRB ID#: 201309067). Under this IRB
protocol no informed consent was required from the patients. Human IF staining
was carried out as follows: IF staining for p16INK4a (p16) and CD45 were used in a
co-staining procedure similar to formalin-ﬁxed, parafﬁn embedded, mouse
sections. Brieﬂy, following deparafﬁnization and rehydration, antigen retrieval was
performed by boiling slides on a hot plate and then allowing slides to cool before
staining. Tissue sections were blocked and then primary antibody applied for
detection of p16 and CD45. After overnight incubation with the primary antibody
at 4 °C, the corresponding secondary antibodies were applied for 1 h at room
temperature. Slides were then washed and mounted using ProLong Gold with
DAPI (Life Technologies) Additional information about antibodies can be found in
Supplementary Table 1.
Human IL-6, p16 IF co-staining used the same techniques stated for p16, CD45
staining. Quantiﬁcation of staining was performed using Fiji software to analyse
MFI per image. Before calculating the MFI, the freehand selection tool was used to
select only the stromal region for MFI quantiﬁcation thus excluding the epithelium
from the analysis. Details regarding antibodies can be found in Supplementary
Table 1.
Human IHC staining was carried out using the following antibodies: CD33
(clone: PWS44, Leica Biosystems, cat. # NCL-L-CD33), CD15 (clone: MY-1, Abcam,
cat. # ab754), CD14 Ab-2 (clone: 7, Thermo Fisher Scientiﬁc, cat. #.
MS-1080), p27 (clone: G173–524, BD Pharmingen, cat. # 554069). Slides were heated
to 60–70 °C for 30 min and then deparafﬁnized in xylene three times, 5 min each.
Tissue was rehydrated through incubation in decreasing grades of ethanol up to
H2O. Antigen retrieval was achieved through incubating slides in citrate buffer in a
pressure cooker (125 °C for 1 min then 95 °C for 20 min, CD33, CD15, CD14), or
boiled for 10 min on a hot plate (p27). Slides were cooled for 20 min and then
peroxidase activity was blocked using 3% H2O2 in PBS for 10 min at room
temperature. Slides were rinsed in PBS and blocked using Dako Serum-free Protein
Block (Dako) for 30 min at room temperature in a humidiﬁed chamber. Following
blocking step, primary antibody was diluted in Dako Antibody Diluent (Dako) and
applied to the slides at an appropriate concentration (CD33 1:100, 4 mg ml  1, CD15
1:10, not puriﬁed, CD14 1:20, not puriﬁed, p27 1:50, 10 mg ml  1). Slides were
incubated on primary antibody overnight at 4 °C in a humidiﬁed chamber. The next
day, slides were washed in PBS and a biotinylated, goat anti-mouse secondary
(Vector Labs, Cat. #. BA-4001, 6 mg ml  1) diluted in Dako Antibody Diluent was
placed on the slides for 30 min at room temperature. Slides were washed in PBS and
ABC-Elite solution (Vector Labs) was then applied for 30 min at room temperature.
Slides were washed in PBS and DAB (Dako) was used to develop the stain. Slides
were counterstained using haematoxylin for 5 min, dipped in bluing reagent 10 times
before being rinsed for 2 min in running water. Tissue sections were dehydrated by
increasing grades of ethanol, cleared with xylene and then mounted. Additional
information about antibodies can be found in Supplementary Table 1.
Microscopy. All bright-ﬁeld images were acquired using a conventional Nikon
microscope and Nikon Elements imaging software. All ﬂuorescent images were
acquired by a Nikon Eclipse Ti-E microscope with automated stage and focus
control driven by Metamorph Software.
Bone marrow isolation and conditioned media treatment. Bone marrow
was isolated from the long bones of wildtype FVB mice via centrifugation.
The bone marrow cells were then cultured in RPMI media þ 5% heat-inactivated
FBS (Sigma) on petri dishes in a 37 °C tissue culture incubator at 5% oxygen,
5% carbon dioxide, balanced with nitrogen. To assess the effects of conditioned
media, the bone marrow cells were plated at 2.5  105 cells per 10 cm dish in either
control RPMI þ 5% heat-inactivated FBS (Sigma) medium, senescent MSF
CM þ 5% heat-inactivated FBS (Sigma), or control MSF CM þ 5% heat-inactivated
FBS (Sigma). For assessing the contribution of IL-6 in this assay, bone marrow
cells were plated with either control media (RPMI media þ 5% heat-inactivated
FBS) or media supplemented with IL-6 (40 ng ml  1) and GM-CSF (40 ng ml  1).
IL-6 neutralized versions of the CM was made as described and used where noted.
Cells were cultured in the above conditions for 4 days before ﬂow cytometry
analysis.
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In vitro T-cell suppression assay. The suppression assay was modiﬁed from
published52 work by ﬁrst isolating bone marrow cells and treating them with
senescent or non-senescent MSF CM as described. Following 96 h of CM
treatment, the cells were collected, counted, and plated in a 96-well plate at
indicated concentrations. Ratios of treated bone marrow cells to splenocytes of 1:1,
1:2, 1:5 and 1:10 were plated such that the number of bone marrow cells per well
equaled 2  105 and the number of splenocytes were adjusted accordingly to meet
the ratios stated. Splenocytes were obtained by physical disruption of a wildtype
FVB spleen, followed by red blood cell lysis and resuspension as a single cell
solution. Splenocytes were stained with CFSE (Invitrogen) at a concentration of
1 mM for 10 min at 37 °C. Untreated bone marrow cells that were not exposed to
CM were used as a control. T cells were stimulated to proliferate using 1 mg ml  1
anti-mouse CD3 antibody (eBioscience). Following 72 h of stimulation, cells were
collected and stained with anti-CD8 antibody to identify the effect on
CD8 þ CFSE þ T-cell proliferation. Experiments were performed in triplicate.
Subcutaneous injections and bioluminescence imaging. MSF cells were injected
in to the ﬂanks of FVB mice, two injections/mouse. Cells were injected at a
concentration of 4  105 cells/injection in 100 ml of a 1:1 solution (DMEM:growth
factor-reduced matrigel (Corning). For co-injection experiments using PDSC5 and
MK16-Ras tumour lines, the MSFs (4  105/injection) were mixed before injection
with either 1.5  105 PDSC5 cells or 100 MK16-Ras cells per injection. Tumour
growth for the MK16-Ras line was monitored using calipers. On day 26, MK16-Ras
tumours were isolated for histological analysis. For the PDSC5 tumour line,
bioluminescence imaging was used to monitor growth with images taken on days 2
and 9 following injection.
Bioluminescence imaging was performed using an IVIS Lumina (PerkinElmer;
Living Image 3.2, 5 min exposure, bin8, FOV12.5 cm, f/stop1, open ﬁlter)53.
Mice were injected intraperitoneally with D-luciferin (150 mg kg  1 in PBS;
Gold Biotechnology) and imaged 10 min later under isoﬂurane anaesthesia
(2% vaporised in O2).
In vitro live-cell bioluminescence imaging was performed on an IVIS 50
(PerkinElmer; Living Image 4.3, 5 min exposure, bin8, FOV12 cm, f/stop1, open
ﬁlter). D-luciferin (150 mg ml  1; Gold Biotechnology) was added to black-walled
plates 10 min before imaging. Total photon ﬂux (photons sec  1) was measured
from ﬁxed regions of interest over the plate or tumours using Living Image 2.6.
Tissue digestion and ﬂow cytometry analysis. Isografts or dorsal skin (FASST
and littermate) were isolated, minced, and transferred to a ﬂask containing collagenase solution (2 mg ml  1 Collagenase A (Sigma), 1 mg ml  1 hyaluronidase
(Sigma), 2 U ml  1 DNase I (Roche) in serum-free DMEM) and a magnetic stir bar.
Flasks were placed on stir plates in a 37° incubator for 1 h. Solution was strained
using a 70 mM cell strainer. Blocking was performed using Fc block (1:200, BD
Pharmingen). Cell surface and intracellular staining was performed.
Concentrations, clones and ﬂuorophore conjugations can be found in
Supplementary Table 1. For FoxP3 intracellular staining, Foxp3/Transcription
Factor Staining Buffer Set (eBioscience) was used according to instructions
(Protocol B). Cell staining was analysed using an LSRII ﬂow cytometer
(Becton Dixon) and FlowJo software (Tree Star).
Neutralizing antibodies and dosing strategies. In vivo neutralizing antibodies
and dosing strategies were as follows: IL-6 neutralizing antibody (clone: MP5-20F3,
BioXcell) or control IgG (IgG1 isotype control, BioXcell) at a dose of 500 mg per
mouse twice weekly starting 1 week before subcutaneous injection, Ly6G neutralizing antibody (clone: 1A8, BioXcell) or control IgG (IgG2a isotype control,
BioXcell) at a dose of 1 mg per mouse for the ﬁrst dose and 500 mg per mouse for
each subsequent dose every 3 days, starting 9 days before subcutaneous cell
injection, CD8 neutralizing antibody (clone: YTS 169.4, BioXcell) at a dose of
250 mg per mouse starting at day  2 and once every 7 days for the duration of the
experiment. All antibodies were delivered by I.P. injection.
IFNc ex vivo activation assay. Isografts were disaggregated as described. For
stimulation, PMA (phorbol 12-myristate 13-acetate) (Sigma), ionomycin (Sigma)
and Brefeldin A (BioLegend) were added at the following concentrations: PMA
50 ng ml  1, ionomycin 0.709 mg ml  1, Brefeldin A 5 ug ml  1. Cells were plated
onto 96-well plates using one well per mouse (2 isografts). The plate was incubated
for 3 h at 37 °C then the contents of each well was transferred to a 1.5 ml eppendorf
tube for staining. Initial cell surface staining was performed as described above
(CD45-PE-Cy7, CD3-APC, CD8-Alexaﬂuor 700) followed by ﬁxation of the cells
using 4% formaldehyde in PBS. After ﬁxation, permeabilization buffer
(BD Bioscience) was added, cells were spun down and resuspended in a wash of
permeabilization buffer then spun down again before resuspension with antibodies
against IFNg or a control IgG (IFNg-PE or IgG-PE). Intracellular staining was
carried out for 1 h on ice in the dark. Cells were washed and transferred to
FACS tubes for analysis using a BD LSRII cytometer (Becton Dixon) and FlowJo
software (Tree Star). Additional information about antibodies can be found in
Supplementary Table 1.
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Spatial and statistical analysis. Spatial analysis of GFP-positive senescent cells
and CD45 positive immune cells was done by manually identifying cells (human
samples) or by using automated cell detection techniques (mouse samples).
Automated cell detection was performed using custom Matlab Software. Before
processing, regions of the image other than the interstitial stroma were masked
(outside the tissue, the epithelial layer, hair follicles, muscle tissue) were masked. In
each image, the median distance from each immune cell to the nearest senescent
cell was computed, providing an estimate of the observed nearest neighbour
distance. The median was chosen over the mean to make this distance statistically
less susceptible to outliers. To determine the distance between immune cells and
senescent cells expected by chance, 100,000 rounds of Monte-Carlo sampling were
performed by randomly placing the immune cells within the unmasked region of
each image. For each round of sampling, the median distance between immune
cells and the nearest senescent cell were recorded. The association score was
computed by subtracting the observed distance from the mean sampling
distance value and normalizing by the s.d. of the sampling distance distribution
(dist_random—dist_observed)/(standard deviation). The score represents the
number of s.d. the observed distance lies from the sampling distance in terms with
positive values indicating association (observed closer than random) and negative
values indicating repulsion (observed farther than random). A value of two
corresponds to an observed median distance o97.5% of the random sampling
median distances.
Statistical Analysis was done by calculating P-values using a standard Student’s
t-test with the exception of the following experiments: CD33 marker counts were
modelled by a generalized mixed effects model with the negative binomial response
distribution to investigate the ﬁxed effect of senescence with the repeated
measurements from various skin samples of each individual donor modelled as a
random effect. For the PDSC5 shIL6 experiment, the fold growth of the log2
transformed BLI between day 9 and day 2 was analysed by a linear model with the
effect of hairpin, the effect of senescence and the interaction between them. For the
experiments on PDSC5 and MK16-Ras competent versus nude mice, log2
transformed BLI and Box-Cox transformed tumour size (with addition of 1 to
accommodate the zeros) were analysed respectively. Note that several
transformations (log, square root and Box-Cox) on the tumour size measurements
were analysed and all gave similar conclusions on the senescence effect. The
Box-Cox transformation (with the parameter estimated as 0.6747 using the
R function ‘boxcox’) resulted in the best goodness-of-ﬁt and was reported.
A linear model was separately ﬁtted on the logged BLI and Box-Cox transformed
tumor size incorporating the effect of mouse strain, the effect of senescence and
their interaction. From the linear models, the effect of senescence within each
hairpin or each strain of mice and the effect difference between hairpins or
strains of mice were estimated and tested. All tests were two-sided and signiﬁcance
was deﬁned at a 5% level. All analyses were conducted in R (version 3.1.1)
(http://www.R-Project.org/).
Data availability. All relevant data are available from the authors.
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